Meet Sarbvir Singh

Life Shaping Upbringing

Why India Is Underinsured

Trust And Literacy Gap

 Policybazaar Growth Engine

Why Build PB Health

Fixing Claims And Processes

GST Premium Impact

Insuring Home Loan Liabilities

PaisaBazaar Credit Pivot

PaisaBazaar Reset Plan

PB Pay Insurance Payments

 Regulation and Compliance

FDI and Market Shifts

 PolicyBazaar Role and Data

UAE and NRI Expansion

 Commission Reform Debate

Mis-selling and Product Clarity

AI in Underwriting

Specialist Insurers and MGAs

Trust and Competition Ahead

Closing Credits

India’s insurance industry is changing faster than ever. New regulations, 100% FDI, AI-powered underwriting, rising medical inflation and Policybazaar’s expansion into healthcare through PB Health are reshaping how Indians will buy—and use—insurance.

In this episode of The Morning Brief, ET’s Anirban Chowdhury speaks with Sarbvir Singh, Joint Group CEO of PB Fintech, on why India remains underinsured, how health insurance is evolving, whether claims can become less painful, the future of retirement planning, and the biggest reforms set to transform the sector over the next five years

India&rsquo;s insurance industry is changing faster than ever. New regulations, 100% FDI, AI-powered underwriting, rising medical inflation and Policybazaar&rsquo;s expansion into healthcare through PB Health are reshaping how Indians will buy&mdash;and use&mdash;insurance.
In this episode of The Morning Brief, ET&rsquo;s Anirban Chowdhury speaks with Sarbvir Singh, Joint Group CEO of PB Fintech, on why India remains underinsured, how health insurance is evolving, whether claims can become less painful, the future of retirement planning, and the biggest reforms set to transform the sector over the next five years

To make sense of the week’s hottest stories in business, economy, politics and markets, journalists from the Economic Times chat with reporters and industry leaders in this thrice-weekly (Tuesday, Thursday, Friday) podcast.

The Morning Brief

The Future of Insurance in India | Sarbvir Singh of PB Fintech

Welcome and Overview

Yano First Hit

From Brown Sugar to Needles

Recovery Warriors Mission

Transit Route Turns Consumer

Seizures and Kingpins

Border Belt User Stories

How the Trade Works

Brown Sugar Dangers

Family and Rehab Support

Community Recovery Model

Nagaland Tribal Law Crackdown

Putting the Crisis in Perspective

The Battle Inside Homes

Closing and Credits

For decades, Northeast India was seen mainly as a corridor for drugs flowing out of Myanmar’s Golden Triangle. That has changed. The transit route is becoming a destination. In this episode of ET Deep Dive, we travel to the Assam–Arunachal Pradesh border, speaking to recovering heroin users, anti-drug volunteers and communities confronting a crisis that is quietly tearing families apart. From schoolchildren drawn into addiction to tribal justice systems stepping in where institutions struggle, this is a story of shifting narcotics networks, broken lives, and remarkable resilience. The battle against drugs is no longer only at the border— it is inside homes.
Shantanu Nandan Sharma reports, Anirban Chowdhury narrates for audio.

For decades, Northeast India was seen mainly as a corridor for drugs flowing out of Myanmar&rsquo;s Golden Triangle. That has changed. The transit route is becoming a destination. In this episode of ET Deep Dive, we travel to the Assam&ndash;Arunachal Pradesh border, speaking to recovering heroin users, anti-drug volunteers and communities confronting a crisis that is quietly tearing families apart. From schoolchildren drawn into addiction to tribal justice systems stepping in where institutions struggle, this is a story of shifting narcotics networks, broken lives, and remarkable resilience. The battle against drugs is no longer only at the border&mdash; it is inside homes. Shantanu Nandan Sharma reports, Anirban Chowdhury narrates for audio.

The East’s Own Overdose

Glenmark’s Innovation Journey

BEAT Platform and New Assets

Partnerships and Global Competition

Glenmark 3.0 and India Access

Why Not CAR-T

Innovation Power Shift

Staying Focused Areas

AI As Innovation Tool

Glenmark Journey Outlook

Glenmark Chairman and Managing Director Glen Saldanha joins Vikas Dandekar and Rica Bhattacharyya to discuss the company’s 25-year innovation bet, and why it’s finally paying off. At the center is ISB2001, a tri-specific antibody partnered with AbbVie, born out of Glenmark’s IGI platform after fifteen years of R&D. Saldanha talks through the platform’s pipeline, why Glenmark stays out of ADCs and CAR-T, how it’s building “Glenmark 3.0” across oncology, dermatology and respiratory, and why he still rates the US well ahead of China on innovation. The conversation also covers India’s licensing deals with Chinese biotechs, AI in drug discovery, and the GLP-1 market.

Listen in

You can follow Vikas Dandekar on his social media: X or Linkedin and Rica Bhattacharyya on her X and Linkedin

Check out other interesting episodes like:ET Deep Dive: Swipe Left on Reality,India wants manufacturing at 25% of GDP — will AI in factories help?, Tanay Kothari Wants To Kill The Keyboard,From Doer to Director: The LinkedIn Playbook for the AI Agea, Semaglutide Goes Generic: Big Pharma’s Moat Breaks  and much more.

Catch the latest episode of ‘The Morning Brief’ on The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Youtube.

Glenmark Chairman and Managing Director Glen Saldanha joins Vikas Dandekar and Rica Bhattacharyya to discuss the company&rsquo;s 25-year innovation bet, and why it&rsquo;s finally paying off. At the center is ISB2001, a tri-specific antibody partnered with AbbVie, born out of Glenmark&rsquo;s IGI platform after fifteen years of R&amp;D. Saldanha talks through the platform&rsquo;s pipeline, why Glenmark stays out of ADCs and CAR-T, how it&rsquo;s building &ldquo;Glenmark 3.0&rdquo; across oncology, dermatology and respiratory, and why he still rates the US well ahead of China on innovation. The conversation also covers India&rsquo;s licensing deals with Chinese biotechs, AI in drug discovery, and the GLP-1 market.
Listen in
You can follow Vikas Dandekar on his social media:&nbsp;<a href="https://twitter.com/VikasReports">X</a> or <a href="https://www.linkedin.com/in/vikas-dandekar-2a0a619">Linkedin</a> and Rica Bhattacharyya on her <a href="https://x.com/RicaB_ET">X</a> and <a href="https://www.linkedin.com/in/rica-bhattacharyya-72b24a11/">Linkedin </a>Check out other interesting episodes like:<a href="https://podcasts.apple.com/in/podcast/et-deep-dive-swipe-left-on-reality/id1568661777?i=1000763614435&amp;l=te">ET Deep Dive: Swipe Left on Reality</a>,<a href="https://podcasts.apple.com/in/podcast/india-wants-manufacturing-at-25-of-gdp-will-ai-in/id1568661777?i=1000760758322">India wants manufacturing at 25% of GDP &mdash; will AI in factories help?</a>, <a href="https://podcasts.apple.com/us/podcast/tanay-kothari-wants-to-kill-the-keyboard/id1568661777?i=1000758892178">Tanay Kothari Wants To Kill The Keyboard</a>,<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000738205536"> </a><a href="https://podcasts.apple.com/in/podcast/from-doer-to-director-the-linkedin-playbook-for-the-ai-age/id1568661777?i=1000756242616">From Doer to Director: The LinkedIn Playbook for the AI Agea</a>, <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000756051799">Semaglutide Goes Generic: Big Pharma&rsquo;s Moat Breaks</a>&nbsp; and<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777"> much more</a>.
Catch the latest episode of &lsquo;The Morning Brief&rsquo; on<a href="https://economictimes.indiatimes.com/podcast?from=mdr"> The Economic Times Online</a>,<a href="https://open.spotify.com/show/6PL5kfPbwURBEu6fHCVTOL?si=26ec0fbfa7134fea"> Spotify</a>,<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777"> Apple Podcasts</a>,<a href="https://www.jiosaavn.com/shows/the-morning-brief/1/GNPiFQD2xpY_"> JioSaavn</a>,<a href="https://music.amazon.in/podcasts/f378141f-9afb-495d-83da-9b08ec5047ac/the-morning-brief"> Amazon Music</a> and<a href="https://www.youtube.com/@theetpodcasts"> Youtube</a>.

Glenmark Chief on Cracking the Multi-Specific Code

Meet the Reporter

Why ISRO Staff Are Leaving

Vacancies Hit 25 Year High

Which Missions Take the Hit

Bureaucracy Pay and Culture

Late Hiring and COVID Fallout

Private Sector Cant Replace ISRO

Can ISRO Rebuild Talent

Wrap Up and Key Takeaways

ISRO is losing people faster than it can hire them. Around 100 scientists and engineers have resigned or taken voluntary retirement recently, with the bulk of the exits from URSC, ISRO's satellite hub, and VSSC, its rocket-making centre. More worryingly, the agency's on-roll strength is now lower than it was in 2001-02, even as its workload has multiplied with Gaganyaan, Chandrayaan-4 and-5, and Venus and Mars missions on the table. TOI's Chethan Kumar, who broke both stories, joins Anirban Chowdhury to unpack what's really driving the attrition, why the private space boom is only part of the story, and what it means for India's space ambitions.

You can follow Anirban Chowdhury on his social media: X and Linkedin

Check out other interesting episodes like:ET Deep Dive: Swipe Left on Reality,India wants manufacturing at 25% of GDP — will AI in factories help?, Tanay Kothari Wants To Kill The Keyboard,From Doer to Director: The LinkedIn Playbook for the AI Agea, Semaglutide Goes Generic: Big Pharma’s Moat Breaks  and much more.

Catch the latest episode of ‘The Morning Brief’ on The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Youtube.

ISRO is losing people faster than it can hire them. Around 100 scientists and engineers have resigned or taken voluntary retirement recently, with the bulk of the exits from URSC, ISRO's satellite hub, and VSSC, its rocket-making centre. More worryingly, the agency's on-roll strength is now lower than it was in 2001-02, even as its workload has multiplied with Gaganyaan, Chandrayaan-4 and-5, and Venus and Mars missions on the table. TOI's Chethan Kumar, who broke both stories, joins Anirban Chowdhury to unpack what's really driving the attrition, why the private space boom is only part of the story, and what it means for India's space ambitions. You can follow Anirban Chowdhury on his social media:<a href="https://twitter.com/AnirbanET"> X</a> and<a href="https://www.linkedin.com/in/anirban-chowdhury-b5067219/"> Linkedin </a>Check out other interesting episodes like:<a href="https://podcasts.apple.com/in/podcast/et-deep-dive-swipe-left-on-reality/id1568661777?i=1000763614435&amp;l=te">ET Deep Dive: Swipe Left on Reality</a>,<a href="https://podcasts.apple.com/in/podcast/india-wants-manufacturing-at-25-of-gdp-will-ai-in/id1568661777?i=1000760758322">India wants manufacturing at 25% of GDP &mdash; will AI in factories help?</a>, <a href="https://podcasts.apple.com/us/podcast/tanay-kothari-wants-to-kill-the-keyboard/id1568661777?i=1000758892178">Tanay Kothari Wants To Kill The Keyboard</a>,<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000738205536"> </a><a href="https://podcasts.apple.com/in/podcast/from-doer-to-director-the-linkedin-playbook-for-the-ai-age/id1568661777?i=1000756242616">From Doer to Director: The LinkedIn Playbook for the AI Agea</a>, <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000756051799">Semaglutide Goes Generic: Big Pharma&rsquo;s Moat Breaks</a>&nbsp; and<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777"> much more</a>.
Catch the latest episode of &lsquo;The Morning Brief&rsquo; on<a href="https://economictimes.indiatimes.com/podcast?from=mdr"> The Economic Times Online</a>,<a href="https://open.spotify.com/show/6PL5kfPbwURBEu6fHCVTOL?si=26ec0fbfa7134fea"> Spotify</a>,<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777"> Apple Podcasts</a>,<a href="https://www.jiosaavn.com/shows/the-morning-brief/1/GNPiFQD2xpY_"> JioSaavn</a>,<a href="https://music.amazon.in/podcasts/f378141f-9afb-495d-83da-9b08ec5047ac/the-morning-brief"> Amazon Music</a> and<a href="https://www.youtube.com/@theetpodcasts"> Youtube</a>.

ISRO's Exodus: Space Crisis, Staff Crisis

The Future of Insurance in India | Sarbvir Singh of PB Fintech

In 1 playlist(s)

The Morning Brief

Social links

Follow podcast

Recent clips